Pfizer Inc plans to ask US regulators to authorise a booster dose of its Covid-19 vaccine within the next month, based on evidence of greater risk of reinfection six months after inoculation and the spread of the highly contagious Delta variant.
Pfizer’s chief scientific officer Mikael Dolsten said the company and BioNTech SE are designing a new version of the vaccine targeting the Delta variant. The companies do not believe that the current version will need to be replaced in order to combat the variant.
Sinovac Biotech Ltd’s vaccine was found to be less potent than that of Pfizer Inc at stopping Covid-19 in Chile, where the two shots were used simultaneously, in the first real-world analysis comparing an inactivated vaccine with one using mRNA. Researchers found that CoronaVac was 66% effective in preventing Covid-19 among fully vaccinated adults, versus 93% for the jab made by Pfizer and its partner BioNTech SE.
Uganda’s President Yoweri Museveni says the country has received green monkey cells, which are critical in its quest to develop a Covid-19 vaccine to address the surge in infections. It will be the first time these cells are used in a laboratory in Africa to multiply the virus for vaccine production.
All individuals who receive Covid-19 vaccines approved by the World Health Organization can enter Europe, the EU delegation to Malaysia clarified on July 7.
For the time being, only children aged 12 to 17 with underlying medical problems will be vaccinated, said National Covid-19 Immunisation Programme coordinating minister Khairy Jamaluddin.